Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,621,344 shares of the company's stock after purchasing an additional 67,571 shares during the quarter. Bank of New York Mellon Corp owned 0.14% of Teva Pharmaceutical Industries worth $35,734,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Stifel Financial Corp lifted its stake in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock worth $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after purchasing an additional 33,277 shares during the last quarter. Thrivent Financial for Lutherans grew its position in Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock valued at $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $24,314,000. Finally, Pinnbrook Capital Management LP purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Teva Pharmaceutical Industries Trading Up 10.0 %

Shares of NYSE TEVA traded up $1.47 during midday trading on Tuesday, reaching $16.14. 19,721,647 shares of the stock were exchanged, compared to its average volume of 12,955,174. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $18.29 billion, a P/E ratio of -11.13, a P/E/G ratio of 1.44 and a beta of 0.82. The stock has a 50 day moving average price of $18.70 and a 200-day moving average price of $18.35. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.